ARTICLE | Distillery Therapeutics
Hepatic
May 3, 2018 4:17 PM UTC
Patient sample and mouse studies suggest inhibiting AEBP1 could help treat non-alcoholic steatohepatitis (NASH). In liver samples from NASH patients, hepatic stellate cell (HSC) levels of AEBP1 were h...
BCIQ Target Profiles